Explore

Trendline Trendline
Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments

Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments

Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments
Trendline Trendline
FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul
Trendline Trendline
Avalyn Pharma Files IPO to Advance Respiratory Disease Treatments

Avalyn Pharma Files IPO to Advance Respiratory Disease Treatments

Avalyn Pharma Files IPO to Advance Respiratory Disease Treatments
Trendline Trendline
FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability

FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability

FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability
Trendline Trendline
GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects

GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects

GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects
Trendline Trendline
NorthStrive Biosciences Initiates U.S. Production of EL-32 for Muscle Preservation in GLP-1 Therapy

NorthStrive Biosciences Initiates U.S. Production of EL-32 for Muscle Preservation in GLP-1 Therapy

NorthStrive Biosciences Initiates U.S. Production of EL-32 for Muscle Preservation in GLP-1 Therapy
Trendline Trendline
IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy
Trendline Trendline
Emalex Biosciences Secures Patent for Innovative Tourette Syndrome Treatment

Emalex Biosciences Secures Patent for Innovative Tourette Syndrome Treatment

Emalex Biosciences Secures Patent for Innovative Tourette Syndrome Treatment
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Lead Cancer Drug Development

Byondis Appoints Christoph Korpus as CEO to Lead Cancer Drug Development

Byondis Appoints Christoph Korpus as CEO to Lead Cancer Drug Development
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Advance Antibody-Drug Conjugate Technology

Byondis Appoints Christoph Korpus as CEO to Advance Antibody-Drug Conjugate Technology

Byondis Appoints Christoph Korpus as CEO to Advance Antibody-Drug Conjugate Technology
Trendline Trendline
Biotechnology and Pharmaceutical Services Outsourcing Market Projected to Reach USD 89.82 Billion by 2035

Biotechnology and Pharmaceutical Services Outsourcing Market Projected to Reach USD 89.82 Billion by 2035

Biotechnology and Pharmaceutical Services Outsourcing Market Projected to Reach USD 89.82 Billion by 2035
Trendline Trendline
Byondis Appoints Christoph Korpus as CEO to Drive Strategic Growth

Byondis Appoints Christoph Korpus as CEO to Drive Strategic Growth

Byondis Appoints Christoph Korpus as CEO to Drive Strategic Growth